Vericiguat for the treatment of heart failure with reduced ejection fraction
暂无分享,去创建一个
R. Mentz | M. Fudim | S. Greene | J. Butler | M. S. Khan | A. Siddiqi
[1] G. Fonarow,et al. Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States. , 2023, JACC. Heart failure.
[2] K. Anstrom,et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum , 2022, European journal of heart failure.
[3] A. Cohen-Solal,et al. Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial , 2022, ESC heart failure.
[4] P. Armstrong,et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial , 2022, European journal of heart failure.
[5] P. Ponikowski,et al. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial , 2022, Circulation. Heart failure.
[6] P. Ponikowski,et al. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF , 2022, Circulation.
[7] A. Bayés‐Genís,et al. Vericiguat in heart failure: From scientific evidence to clinical practice. , 2022, Revista clinica espanola.
[8] A. Miranda,et al. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. , 2022, Journal of pharmacy practice.
[9] D. Trenk,et al. Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study , 2022, Clinical and translational science.
[10] G. Mikus,et al. Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study , 2022, Clinical pharmacology and therapeutics.
[11] Chia‐Pin Lin,et al. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study , 2022, Frontiers in Cardiovascular Medicine.
[12] Josip A. Borovac,et al. Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift , 2022, Expert review of cardiovascular therapy.
[13] D. Lautsch,et al. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective , 2021, PharmacoEconomics.
[14] K. Frey,et al. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure , 2021, The Annals of pharmacotherapy.
[15] P. Ponikowski,et al. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). , 2021, Circulation.
[16] Mahesh J. Patel,et al. Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. , 2021, Journal of cardiac failure.
[17] P. Ponikowski,et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial , 2021, European journal of heart failure.
[18] P. Ponikowski,et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial , 2021, European journal of heart failure.
[19] D. Lautsch,et al. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event , 2021, Advances in Therapy.
[20] M. Khan,et al. Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care. , 2021, Journal of the American College of Cardiology.
[21] K. Sliwa,et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. , 2020, JAMA cardiology.
[22] M. Boettcher,et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects , 2020, European Journal of Clinical Pharmacology.
[23] K. Pogue,et al. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension , 2020, Journal of pharmacy practice.
[24] Sanjiv J. Shah,et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. , 2020, JAMA.
[25] M. Emdin,et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[26] M. Boettcher,et al. Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers , 2020, Clinical Pharmacokinetics.
[27] P. Ponikowski,et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. , 2020, JACC. Heart failure.
[28] M. Radtke,et al. Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies , 2020, Clinical Pharmacokinetics.
[29] P. Ponikowski,et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.
[30] A. Rigby,et al. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. , 2019, Journal of the American College of Cardiology.
[31] M. Khan,et al. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease. , 2019, The American journal of cardiology.
[32] Mahesh J. Patel,et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.
[33] G. Felker,et al. Outpatient Worsening Heart Failure as a Target for Therapy: A Review , 2018, JAMA cardiology.
[34] M. Bots,et al. Trends in comorbidity in patients hospitalised for cardiovascular disease. , 2017, International journal of cardiology.
[35] P. Ponikowski,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.
[36] H. Trübel,et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. , 2017, Journal of medicinal chemistry.
[37] G. Francis,et al. Heart Failure with Preserved Ejection Fraction (HFpEF) , 2017 .
[38] Sanjiv J. Shah,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.
[39] Sanjiv J. Shah,et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) , 2014, European journal of heart failure.
[40] Talicia Tarver,et al. HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION , 2014 .
[41] Chen Wang,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.
[42] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[43] P. Ponikowski,et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure , 2013, Heart Failure Reviews.
[44] Robert O. Bonow,et al. Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.
[45] M. Gheorghiade,et al. Role of guanylate cyclase modulators in decompensated heart failure , 2009, Heart Failure Reviews.
[46] P. Jhund,et al. Heart Failure with Reduced Ejection Fraction , 2019, Textbook of Vascular Medicine.
[47] Lothar Roessig,et al. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. , 2017, Handbook of experimental pharmacology.
[48] Laura Marshall,et al. Heart failure with reduced ejection fraction , 2017, Nature Reviews Disease Primers.